Journals / Dicle Tıp Dergisi / 2021 / Cilt: 48 - Sayı: 2

Association of Initial HbA1c Level with Obesity Medical Treatment Success in Morbidly Obese Patients

Morbid Obez Hastalarda Obezite Medikal Tedavi Başarısı ile Başlangıç HbA1c Düzeyi İlişkisi

Pages
316–327
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusions: When pharmacological treatment is given together with a three-month lifestyle change in newly diagnosed morbid obese patients, it can be predicted that more effective weight loss may occur in those with a high initial HBA1c level.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Significant clinical benefits of 5-10% weight loss in obesity have been shown at the beginning to reduce comorbidities.
📊
Key Findings & Data:Methods: In this retrospecific study, anthropometric measurements, blood pressure, lipid profile, fasting glucose and insulin levels, liver enzymes and HBA1c levels were determined before treatment after three-month lifestyle change and pharmacological treatment of 58 newly diagnosed morbid obese patients without previously known comorbid diseases and the results after treatment were compared.
💡
Conclusion & Impact:Conclusions: When pharmacological treatment is given together with a three-month lifestyle change in newly diagnosed morbid obese patients, it can be predicted that more effective weight loss may occur in those with a high initial HBA1c level.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: Significant clinical benefits of 5-10% weight loss in obesity have been shown at the beginning to reduce comorbidities. In this study, it was investigated whether effective weight loss at the end of three months of lifestyle change and pharmacological treatment in newly diagnosed morbidly obese patients could be predicted by basal clinical parameters. Methods: In this retrospecific study, anthropometric measurements, blood pressure, lipid profile, fasting glucose and insulin levels, liver enzymes and HBA1c levels were determined before treatment after three-month lifestyle change and pharmacological treatment of 58 newly diagnosed morbid obese patients without previously known comorbid diseases and the results after treatment were compared. Weight loss rates were calculated according to baseline and were grouped as <5% (group 1, n = 13), 5-10% (group 2, n = 24), and ≥10% (group 3, n = 21). Results: While the median initial body-mass index was 42.78 kg/m2, it had regressed to 39.96 kg/m2 at the end of three months. Median weight loss was 9 kg (interquartile range, 6–13 kg). The mean basal HBA1c level was the highest in group 3.A positive significant correlation was observed between the basal mean HBA1c level and weight loss according toPearson correlation analysis (rho: 0.468, p <0.001). When multivariate logistic regression analysis was created withbaseline clinical and laboratory parameters to predict more than 10% weight loss, only the basal HBA1c level was foundto be significant (Odds ratio = 5.2 [95% confidence interval 1.03–26.15], p <0.05). Conclusions: When pharmacological treatment is given together with a three-month lifestyle change in newly diagnosed morbid obese patients, it can be predicted that more effective weight loss may occur in those with a high initial HBA1c level.

Özet

Giriş: Komorbiditelerin azaltılmasına yönelik başlangıçta %5-10 kilo kaybının obezitede önemli klinik yararları gösterilmiştir. Bu çalışmada, yeni tanı morbid obezlerde üç aylık yaşam tarzı değişikliği ve farmakolojik tedavinin sonunda etkili kilo kaybının bazal klinik parametreler ile öngörülüp öngörülemeyeceği araştırıldı. Yöntemler: Retrospesifik olarak yapılan bu çalışmada, daha önce bilinen komorbid hastalığı olmayan, 58 yeni tanı morbid obez hastanın üç aylık yaşam tarzı değişikliği ve farmakolojik tedavi sonrasında antropometrik ölçümler, kan basıncı, lipit profili, açlık glukoz ve insülin düzeyi, karaciğer enzimleri ve HBA1c düzeyinin tedavi öncesi ve tedavi sonrasındaki sonuçları karşılaştırıldı. Başlangıca göre kilo kaybı oranları hesaplanıp %5' in altında (grup 1, n = 13), %5–10 (grup 2, n = 24), %10' un üstünde (grup 3, n = 21) kilo kaybedenler olarak gruplandırıldı. Bulgular: Başlangıç vücut-kitle indeksi medyan 42.78 kg/m2 iken üç ay sonunda medyan 39.96 kg/m2'ye gerilemişti. Medyan kilo kaybı 9 kg (çeyreklerarası aralık, 6–13 kg) bulundu. Ortalama bazal HBA1c düzeyi, grup 3' te en yüksek izlendi. Bazal ortalama HBA1c düzeyi ile kilo kaybı arasında Pearson korelasyon analizine göre pozitif yönde anlamlı korelasyon izlendi (rho: 0.468, p < 0.001). %10' dan fazla kilo kaybını öngörmek için bazal klinik ve laboratuar parametreleri ile multivaryant logistik regresyon analizi oluşturulduğunda sadece bazal HBA1c düzeyi anlamlı bulundu (Odds ratio = 5.2 [%95 Güven aralığı 1.03–26.15], p < 0.05). Sonuç: Yeni tanı morbid obezlerde üç aylık yaşam tarzı değişikliği ile beraber farmakolojik tedavi verildiğinde başlangıç HBA1c düzeyi yüksek olanlarda daha etkili kilo kaybının olabileceği ön görülebilir.

🔖

Cite This Article

GÜVEN, M. (2021). Association of Initial HbA1c Level with Obesity Medical Treatment Success in Morbidly Obese Patients. Dicle Tıp Dergisi, Cilt: 48 - Sayı: 2, 316–327. https://ajindex.com/articles/348766

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Satman I, Omer B, Tutuncu Y, et al. Twelve-yeartrends in the prevalence and risk factors of diabetesand prediabetes in Turkish adults. Eur J Epidemiol.2013
  2. Wing RR, Lang W, Wadden TA, et al. Benefits ofmodest weight loss in improving cardiovascular riskfactors in overweight and obese individuals withtype 2 diabetes. Diabetes Care. 2011
  3. Perreault L, Apovian C. Obesity in adults:Overview of management. In: UpToDate, Pi-SunyerFX, Seres D (Ed), UpToDate, Kunins L. ( Accessed onApril 28, 2020) 4.Durrer Schutz D, Busetto L, Dicker D, et al.:European Practical and Patient-Centred Guidelinesfor Adult Obesity Management in Primary Care.Obes Facts. 2019
  4. Tamura BK, Bell CL, Masaki KH, Amella EJ. Factorsassociated with weight loss, low BMI, andmalnutrition among nursing home patients: asystematic review of the literature. J Am Med DirAssoc. 2013
  5. Apolzan JW, Venditti EM, Edelstein SL, et al. Long-Term Weight Loss With Metformin or LifestyleIntervention in the Diabetes Prevention ProgramOutcomes Study. Ann Intern Med. 2019
  6. Dombrowski SU, Knittle K, Avenell A, Araújo-Soares V, Sniehotta FF. Long term maintenance ofweight loss with non-surgical interventions in obeseadults: systematic review and meta-analyses ofrandomised controlled trials. BMJ. 2014
  7. Tang Q, Li X, Song P, Xu L. Optimal cut-off valuesfor the homeostasis model assessment of insulinresistance (HOMA-IR) and pre-diabetes screening:Developments in research and prospects for the future. Drug Discov Ther. 2015
  8. Yumuk V, Tsigos C, Fried M, et al. EuropeanGuidelines for Obesity Management in Adults. ObesFacts. 2015
  9. Garvey WT, Mechanick JI, Brett EM, et al.Amerıcan Assocıatıon of Clınıcal Endocrınologıstsand Amerıcan College of EndocrınologyComprehensıve Clınıcal Practıce Guıdelınes ForMedıcal Care of Patıents Wıth Obesıty. Endocr Pract.2016
  10. US Food and Drug Administration. FDA-approved drug products: Contrave. 2014.http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/200063s000lbl.pdf. Accessed April 26,2016. 12.NCD Risk Factor Collaboration (NCD-RisC).Worldwide trends in body-mass index,underweight, overweight, and obesity from 1975 to2016: a pooled analysis of 2416 population-basedmeasurement studies in 128·9 million children,adolescents, and adults. Lancet. 2017
  11. Bray GA, Kim KK, Wilding JPH
  12. World ObesityFederation. Obesity: a chronic relapsing progressivedisease